Klotho Neurosciences (KLTO) stock rocketed higher on Monday after the biopharmaceutical company announced a new approach that could extend patient lifespan. The company’s pre-clinical data suggested that it could replace the silenced α-KLOTHO gene to achieve this goal.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
According to Klotho Neurosciences, “genetic over expression of the full-length form of Klotho in mice, increased in lifespan of mice of up to 30%-40% longer compared to the normal mouse lifespan.” The company notes it has an exclusive worldwide license to s-KL, a treatment based on this study that could work on neurodegenerative and age-related disorders.
News of the study data and exclusive license sent shares of KLTO stock soaring 175.61% in pre-market trading on Monday. However, the shares are still down 96.28% over the past 12 months.
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue